This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stifel Nicolaus Sticks to Its Buy Rating for Incyte (INCY)

Tipranks - Tipranks - Tue Jun 16, 9:42AM CDT

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Incyte, with a price target of $123.00.

Claim 55% Off TipRanks

According to TipRanks, Willey is a 4-star analyst with an average return of 6.7% and a 43.62% success rate. Willey covers the Healthcare sector, focusing on stocks such as Incyte, Insmed, and Syndax Pharmaceuticals.

In addition to Stifel Nicolaus, Incyte also received a Buy from Barclays’s Etzer Darout in a report issued today. However, on the same day, Goldman Sachs maintained a Hold rating on Incyte (NASDAQ: INCY).

See the top stocks recommended by analysts >>

Based on Incyte’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.27 billion and a net profit of $303.33 million. In comparison, last year the company earned a revenue of $1.05 billion and had a net profit of $158.2 million

Based on the recent corporate insider activity of 103 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Earlier this month, Thomas Tray, the CAO of INCY sold 2,639.00 shares for a total of $263,900.00.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).